Download PDF
Thromb Haemost 2007; 97(03): 498-499
DOI: 10.1160/TH06-10-0598
Letters to the Editor
Schattauer GmbH

Perioperative bridging with fondaparinux in a woman with antithrombin deficiency

Rupert Bauersachs
1   Medizinische Klinik IV, Klinikum Darmstadt, Darmstadt, Germany
,
Susanne Alban
2   Pharmazeutisches Institut, Abteilung Pharmazeutische Biologie, Christian-Albrechts-Universität zu Kiel, Kiel, Germany
› Author Affiliations
Further Information

Publication History

Received 23 October 2006

Accepted after revision 03 January 2007

Publication Date:
28 November 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Turpie AG. The safety of fondaparinux for the prevention and treatment of venous thromboembolism. Expert Opin Drug Saf 2005; 4: 707-721.
    CrossrefPubMedGoogle Scholar
  • 2 Bauer KA. Fondaparinux: a new synthetic and selective inhibitor of Factor Xa. Best Pract Res Clin Haematol 2004; 17: 89-104.
    CrossrefPubMedGoogle Scholar
  • 3 Spyropoulos AC, Turpie AG. Perioperative bridging interruption with heparin for the patient receiving long-term anticoagulation. Curr Opin Pulm Med 2005; 11: 373-379.
    PubMedGoogle Scholar
  • 4 Levy JH. Heparin resistance and antithrombin: should it still be called heparin resistance?. J Cardiothorac Vasc Anesth 2004; 18: 129-130.
    CrossrefPubMedGoogle Scholar
  • 5 Olson ST, Bjork I, Sheffer R. et al. Role of the antithrombin- binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. J Biol Chem 1992; 267: 12528-12538.
    PubMedGoogle Scholar
  • 6 Paolucci F, Clavies MC, Donat F. et al. Fondaparinux sodium mechanism of action: identification of specific binding to purified and human plasma-derived proteins. Clin Pharmacokinet 2002; 41 (Suppl. 02) 11-18.
    CrossrefPubMedGoogle Scholar
  • 7 Donat F, Duret JP, Santoni A. et al. The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet 2002; 41 (Suppl. 02) (Suppl) 1-9.
    PubMedGoogle Scholar
  • 8 Hirsh J, Raschke R. Heparin and low-molecularweight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (Suppl. 03) (Suppl) 188S-203S.
    CrossrefPubMedGoogle Scholar
  • 9 Beguin S, Welzel D, Al Dieri R. et al. Conjectures and refutations on the mode of action of heparins. The limited importance of anti-factor Xa activity as a pharmaceutical mechanism and a yardstick for therapy. Haemostasis 1999; 29: 170-178.
    PubMedGoogle Scholar
  • 10 Al Dieri R, Alban S, Beguin S. et al. Fixed dosage of low-molecular-weight heparins causes large individual variation in coagulability, only partly correlated to body weight. J Thromb Haemost 2006; 4: 83-89.
    PubMedGoogle Scholar
  • 11 Ansell J, Hirsh J, Poller L. et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (3 Suppl): 204S-233S. Erratum in: Chest 2005; 127: 415-416.
    PubMedGoogle Scholar
  • 12 Yusuf S, Mehta SR, Chrolavicius S. et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006; 354: 1464-1476.
    CrossrefPubMedGoogle Scholar
  • 13 Yusuf S, Mehta SR, Chrolavicius S. et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. J Am Med Assoc 2006; 295: 1519-30.
    CrossrefPubMedGoogle Scholar